What question did this study set out to answer?

The research aims to evaluate molecular features, prognosis, and therapeutic strategies for small-cell carcinoma of the ovary hypercalcaemic type.

March 12, 2026Open Access

34P Small-cell carcinoma of the ovary hypercalcaemic type (SCCOHT): A systematic review of molecular features, prognosis and therapeutic strategies

Key Points

The research aims to evaluate molecular features, prognosis, and therapeutic strategies for small-cell carcinoma of the ovary hypercalcaemic type.
Performed a prospective analysis of 182 patients with rare gynaecological tumors.
Used a virtual multidisciplinary tumor board to discuss cases from April 2023 to April 2025.
Collected data on diagnostic reviews, management concordance, clinical trial enrollment, and patient outcomes.
Increased case volume over time, reflecting enhanced collaborative involvement.
Molecular analysis or expert review recommended in 12% of cases.
53.3% of patients had their treatment strategy adjusted; expert recommendations were followed in 69.2% of cases.

Abstract

Background: Rare gynaecological tumours (RGTs) represent a highly heterogeneous group of malignancies, often with more limited clinical evidence and expertise in their management unevenly distributed across Europe.Evidence on optimal treatment is often limited, contributing to delayed diagnosis, suboptimal treatment, and unequal access to innovative therapies.The EURACAN-G2 domain established a transnational virtual multidisciplinary monthly tumour board (vMDT) to reduce disparities and enhance clinical decision-making for patients with RGTs. Methods:A prospective analysis of 182 consecutive patients with RGTs (including rare ovarian, uterine, cervical, vaginal, and vulvar subtypes) discussed within the EURACAN G2 vMDT between April 2023 and April 2025 was performed.A median of 17 (8-25) attendees were connected.Recommendations were released immediately after the EURACAN vMDT.Data collected included the impact of diagnostic review, the level of concordance between management proposed by the expert centre and EURACAN vMDT adherence to those recommendations, enrolment in clinical trials or off-label drug therapy and patient status.Results: Patients originated from 14 European countries and 3 non-European countries.The number of monthly cases presented was 6-12.Case volume increased steadily over time, indicating strengthened involvement across the network.In 37 (12%) cases, a relevant additional molecular analysis or expert review was recommended.For 97 (53.3%) patients, the therapeutic strategy was adjusted.Expert recommendations were followed in 126 (69.2%) cases, and 41 (22.5%) patients gained access to innovative therapies or clinical trials. Conclusions:The EURACAN G2 vMDT effectively addresses inequalities in care for patients with RGTs by enhancing access to expert knowledge, promoting centralised pathology review, and enabling patients to be referred to highly specialised treatment settings.This model strengthens the role of ERNs in improving the standard of care for RGTs in Europe and demonstrates its potential for transferability to other rare tumour domains.

Mark Helpful

Bookmark

Relay

View Full Paper